Physician profile

Amanda Dewitt

Atlantis, FL

NPI 1538928072

$964.01

in general payments reported to CMS, 2019-2025

4 companies · $964 in 2025

The $964 reported for 2025 was more than what 87% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$808.01
Education$156.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $550.39 2025 Inbone, Prostep
Polynovo North America LLC $152.11 2025 Novosorb Btm
Organogenesis INC. $147.96 2025 Apligraf, Affinity, Puraply Wound Matrix
Southern Edge Orthopaedics, INC. $113.55 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amanda Dewitt

$964.01

in general payments reported 2019-2025

Years
2025
Top company
Stryker Corporation
Context
The $964 reported for 2025 was more than what 87% of providers received nationally.

https://glasscript.com/doctor/11968263/amanda-dewitt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.